XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
  Virology
   West Nile Virus
  Bacteriology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Aug 19th, 2006 - 22:18:38

Virology Channel
subscribe to Virology newsletter

Latest Research : Microbiology : Virology

   DISCUSS   |   EMAIL   |   PRINT
Adenovirus may deliver bird flu vaccine
Sep 14, 2005, 01:46, Reviewed by: Dr.

"The ultimate goal of our research is to develop an effective avian influenza virus vaccine that will provide long-lasting and broad immunity against multiple strains of this virus"

 
A harmless virus used as a delivery vehicle may help set a roadblock for a potentially catastrophic human outbreak of bird flu, according to researchers at Purdue University and the Centers for Disease Control and Prevention (CDC).

Purdue molecular virologist Suresh Mittal and his collaborators are investigating a new way to provide immunity against avian influenza viruses, or bird flu, the most lethal of which, H5N1, has a 50 percent fatality rate in humans. Under a $1.6 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), the researchers are focusing on using a harmless virus, called adenovirus, as a transmitting agent for a vaccine to fight off highly virulent strains of the avian influenza viruses.

Current vaccines are designed for strains of flu found in local areas and are effective only as long as the virus doesn't change form. Existing vaccines will have limited success against new strains of avian influenza, he said. Every time a bird flu mutates, vaccines must be redesigned.

An additional important advantage to using an adenovirus as a vector, or transporter of vaccine into cells, is that is could be mass produced much more quickly than with current methods.

"Our approach is to use an adenovirus to deliver some components of the bird flu virus in a vaccine formulation," Mittal said. "We already know how to grow large amounts of adenovirus and how to purify it because adenoviruses already are used in clinical trials for gene therapy as vectors."

Mittal and collaborators Harm HogenEsch, co-principal investigator and head of Purdue's Department of Veterinary Pathobiology, and Jacqueline Katz and Suryaprakash Sambhara, both co-investigators from the CDC, are focused on creating better protection against the constantly mutating avian influenza viruses.

"The ultimate goal of our research is to develop an effective avian influenza virus vaccine that will provide long-lasting and broad immunity against multiple strains of this virus," Mittal said.

The proteins that form the basis for all of today's flu vaccines are grown in fertilized chicken eggs. It takes months to produce a new vaccine for a new virus strain using this method and limits vaccine supplies due to shortages in eggs for the purpose. The egg production method also creates difficulty in redesigning vaccine to keep pace with virus mutations.

"Do we still want to depend on the egg to make our flu vaccines?" Mittal said. "When these types of viruses strike humans, they also strike poultry. In that case, the availability of fertilized eggs to make enough vaccine will be compromised."

Even with a recently developed vaccine based on growing a single protein of H5N1, it would be difficult to rapidly produce enough protective medication to stem a pandemic, according to experts from the CDC, World Health Organization and NIAID. However, a large quantity of an adenovirus-based vaccine could easily be produced on short notice, Mittal said.

A "medium-level" bird flu pandemic in the United States would kill between 90,000 and 200,000 people with another 20 million to 47 million more sickened, CDC experts estimate. The economic impact on the United States alone would be between $71.3 billion and $166.5 billion.

Influenza viruses are respiratory pathogens responsible for widespread infections in humans, a variety of birds, marine mammals, pigs and horses. In Southeast Asia, millions of poultry have died or been euthanized because of H5N1 avian influenza.

Before the human cases of H5N1, there were no known cases of bird-to-human transmission that led to significant disease, Mittal said. However, this type of flu already has passed from poultry to people who had direct contact with ill birds or contact with contaminated bird feces, saliva or nasal mucous. A few cases have been documented of human-to-human infection, according to the World Health Organization.

In addition, migratory waterfowl at China's Qinghai Lake Nature Reserve have succumbed to H5N1. While migratory birds often can pass avian influenza to other animals, they generally don't become ill. Scientists from the U.S. Geological Survey National Wildlife Health Center believe this is further evidence that H5N1 could trigger a human flu pandemic. No cases of this type of bird flu have been found in the United States.

Since 2003 about 60 people have died in Southeast Asia from H5N1, about half of those afflicted. Outbreaks of H5N1 in birds have been confirmed in 11 countries, and the disease is spreading north into countries outside of Southeast Asia and already has been reported in Russia. The disease's spread, occurrences of other bird flu types and the already confirmed human cases, provide added impetus for finding more effective vaccine protection, Mittal said. The CDC reported two human cases of another bird flu in the United States in recent years - H7N2 in Virginia in 2002 and in New York in November 2003.

Viruses are classified according to the combination of two types of proteins found on the virus cell surface. The 15 types of hemagglutinin (H) protein and nine types of neuraminidase (N) protein form a large number of influenza viruses for which birds are the natural hosts.

New, often more dangerous, flu strains develop when the H and N combinations change. When the genes of a human or swine influenza mix with an avian variety, a highly pathogenic human flu likely will result, Mittal said.

These virus alterations work a bit like a jigsaw puzzle: As two viruses grow in the same animal, they replicate and reassemble their genome. If one virus takes a piece of genome from the other virus to fill an empty spot, then a new virus is born.

The potential for a pandemic exists when one of these new viruses is introduced into the human population. People with no previous exposure to this new flu strain have little or no immunity, making them highly susceptible to a virus that now can easily spread from person to person.

The last pandemic was 1968-69 when 34,000 Americans died of the Hong Kong flu (H3N2), a disease still circulating. In 1957-58 Asian flu (H2N2) killed 70,000 people in the United States. The worst flu pandemic was in 1918-19 when Spanish flu (H1N1) was fatal to 500,000 in the United States and as many as 50 million worldwide. Unlike other influenza outbreaks, the origin of that virus is still unknown.

Scientists believe that without the right vaccines and preparation, H5N1 has the potential to be one of the deadliest flu outbreaks if it mutates to easy human-to-human transmission. This flu strain was first identified in South Africa in 1961, with the first bird-to-human case recorded in 1997.

"Many people believe that this virus will mutate and become more widespread," Mittal said. "The question is when? Are we prepared? We hope that successful completion of this project will result in development of an adenovirus-based vaccine effective against pathogenic avian influenza viruses."
 

- Purdue University and the Centers for Disease Control and Prevention (CDC).
 

purdue.edu

 
Subscribe to Virology Newsletter
E-mail Address:

 

HogenEsch and Mittal are both members of the Center for Comparative Medicine, a collaboration of Purdue's College Agriculture, School of Veterinary Medicine and the Indiana University Medical School. The center researches animal and human diseases to find new treatments and cures.

Writer: Susan A. Steeves, (765) 496-7481, [email protected]

Sources: Suresh Mittal, (765) 496-2894, [email protected]

Harm HogenEsch, (765) 494-0596, [email protected]

Ag Communications: (765) 494-2722;
Beth Forbes, [email protected]


Related Virology News

How West Nile virus evades immune defenses
Innovative method for creating a human cytomegalovirus vaccine outlined
Cracking Virus Protection Shield
Viruses trade-off between survival and reproduction
New hybrid virus provides targeted molecular imaging of cancer
Mass spectrometry to detect norovirus particles
xCT molecule is a major gateway for KSHV to enter human cells
Surprising discovery about the inner workings of vesicular stomatitis virus (VSV)
New human retrovirus - Xenotropic MuLV-related virus (XMRV)
Viruses can be forced to evolve as better delivery vehicles for gene therapy


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us